Wealthcare Advisory Partners’s Amphastar Pharmaceuticals AMPH Stock Holding History

Wealthcare Advisory Partners’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-60	Closed	-$1K	–	603
2021 Q1	$1K	Buy	+60	New	+$1.12K	﹤0.01%	1953
2020 Q2	–	Sell	-1,060	Closed	-$16K	–	360
2020 Q1	$16K	Hold	1,060	–	–	﹤0.01%	784
2019 Q4	$20K	Hold	1,060	–	–	﹤0.01%	756
2019 Q3	$21K	Buy	+1,060	New	+$22.1K	﹤0.01%	732

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Wealthcare Advisory Partners's AMPH Position: Q2 2021 in Review

Wealthcare Advisory Partners sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2021, closing a stake of 60 shares — an estimated $1K sold.

Wealthcare Advisory Partners first reported a position in AMPH in Q3 2019 and held it in 4 quarters. The position peaked at $21K in Q3 2019. 146 funds tracked by Wall St. Rank hold AMPH as of Q2 2021.

Wealthcare Advisory Partners reported no remaining Amphastar Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Wealthcare Advisory Partners sold 60 Amphastar Pharmaceuticals shares in Q2 2021, an estimated $1K.
Wealthcare Advisory Partners first reported a position in Amphastar Pharmaceuticals in Q3 2019 and held it in 4 quarters.
Wealthcare Advisory Partners's Amphastar Pharmaceuticals position peaked at $21K in Q3 2019.
146 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2021.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2021, filed 16 Aug 2021.